Cor Vasa 2006, 48(1):32-34
FIELD (Fenofibrate Intervention and Event Lowering in Diabetes)
- 1 Interní-kardiologická klinika, Fakultní nemocnice Brno
- 2 I. interní-kardioangiologická klinika, Fakultní nemocnice u sv. Anny, Brno, Česká republika
The FIELD study was presented at the American Heart Association (AHA) annual meeting held in Dallas, Texas, USA in November 2005 and published simultaneously in The Lancet. The study was designed to assess, in a total of 9,795 patients with diabetes, the effect of fenofibrate vs. placebo in individuals with normal or mildly increased cholesterol and triglycerides > 5 mmol/l. The study demonstrated a decrease in cardiovascular events (p = 0.035); this, however, was associated with a non-significant rise in total (p = 0.18) and cardiovascular mortality (p = 0.41). FIELD documented the safety of fibrate therapy with an incidence of side effects > 1.0%.
Keywords: Diabetes mellitus; Dyslipidemia; Fenofibrate; Cardiovascular risk
Published: January 1, 2006 Show citation
References
- Laakso M, Voutilainen E, Sarlund H, et al. Serum lipids and lipoproteins in middle aged non insulin dependent diabetics. Atherosclerosis 1985;56:271-81.
Go to original source... 
Go to PubMed... - Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-28. Go to original source...
- Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridemia as a risk faktor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989;32:300-4. Go to original source... Go to PubMed...
- Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non inzulin dependent diabetes. Atheroscler Tromb 1992;12:1496-502. Go to original source...
- Frick MH, Elo O, Haapa K, et al. Helsinky Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45. Go to original source... Go to PubMed...
- Koskinen P, Mantari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinky Heart Study. Diabetes Care 1992;15:820-5. Go to original source... Go to PubMed...
- Keatking GM, Ormrod D. Micronised fenofibrate. An update review of its clinical efficasy in the management dyslipidemia. Drugs 2002;62:1909-44. Go to original source... Go to PubMed...
- The FIELD investigators: The need for a large-scale trial of fibrate therapy in diabetes: the rationale, design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabet 2004;3:9-20. Go to original source...
- Rubins HF, Robins SJ, Collins D, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density lipoprotien cholesterol Intervention Trial study group. N Engl J Med 1991;341: 410-8. Go to original source... Go to PubMed...
- Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomised controlled trial. JAMA 2001;285:1585-91. Go to original source... Go to PubMed...
- The BIP study group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7. Go to original source... Go to PubMed...
- The DAIS study group: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet 2001;357:905-10. Go to original source...
- The Field study investigators: Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; v tisku.